Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

C Gasperini, S Haggiag, S Ruggieri - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system (CNS), traditionally considered to be an autoimmune disease. Despite the standard …
被引用次数：12 相关文章

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.

C Gasperini, S Haggiag, S Ruggieri - Expert Opinion on …, 2013 - europepmc.org
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS), traditionally considered to be an autoimmune disease. Despite the standard of care …

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

C Gasperini, S Haggiag, S Ruggieri - EXPERT OPINION ON …, 2013 - iris.uniroma1.it
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system (CNS), traditionally considered to be an autoimmune disease. Despite the standard …

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

C Gasperini, S Haggiag… - Expert opinion on …, 2013 - pubmed.ncbi.nlm.nih.gov
Introduction Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system (CNS), traditionally considered to be an autoimmune disease. Despite the standard …